Your session is about to expire
← Back to Search
Checkpoint Inhibitor
Lerapolturev for Melanoma
Phase 2
Waitlist Available
Research Sponsored by Istari Oncology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
Study Summary
This trial is testing a new cancer drug to see if it is effective and safe when used alone or with another cancer drug.
Who is the study for?
This trial is for adults with advanced melanoma that has worsened despite treatment with FDA-approved anti-PD-1/L1 therapy. Participants must be in good physical condition, not have certain types of melanoma or severe diseases, and agree to use contraception. They should also be willing to undergo tumor biopsies.Check my eligibility
What is being tested?
The study is testing lerapolturev alone or combined with an anti-PD-1 checkpoint inhibitor to see how effective and safe they are for treating melanoma that hasn't responded to previous PD-1 inhibitors.See study design
What are the potential side effects?
Potential side effects may include typical immune-related reactions such as inflammation in various organs, flu-like symptoms, fatigue, skin reactions at the injection site, and possibly others depending on individual health conditions.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Changes from baseline in PD-L1 expression
Neoplasms
Frequency and severity of adverse events of special interest (AESIs and AEs)
+3 moreSecondary outcome measures
DCR-6 months
Disease Control Rate
Durable Response Rate
+3 moreOther outcome measures
DCR based on iRECIST
DCR based on subgroup
DCR-6mo based on iRECIST
+10 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Arm 2: Lerapolturev and anti-PD-1Experimental Treatment2 Interventions
Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 or 4 weeks thereafter. Anti-PD-1 therapy given as per the anti-PD-1 approved package insert.
Group II: Arm 1: Lerapolturev OnlyExperimental Treatment1 Intervention
Lerapolturev (up to 1.6x10^9 TCID50) administered via direct injection of up to 6 lesions given weekly for 7 weeks, followed by every 3 weeks thereafter.
Find a Location
Who is running the clinical trial?
Istari Oncology, Inc.Lead Sponsor
12 Previous Clinical Trials
363 Total Patients Enrolled
2 Trials studying Melanoma
12 Patients Enrolled for Melanoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You need to take medication to prevent blood clots and cannot stop taking it for a few days before and after receiving each lerapolturev injection.You have or had an autoimmune disease or a weakened immune system within the past 2 years.If you're not sure if you got the vaccine, you need to show evidence that you are protected against the disease before joining the study.You have at least two melanoma growths that can be measured by a ruler or imaging tests according to specific guidelines.You have received a transplant with someone else's cells or organs in the past.You have melanoma that affects specific parts of the body such as the eyes, palms of the hands, soles of the feet, or mucous membranes.You have a medical condition that would make it unsafe or difficult for you to participate in the study, or make it hard to accurately measure the study's outcomes.You are expected to live for at least 12 more weeks.You have pain that is not being managed by current treatments and is caused by the tumor.You have cancerous growths that can be treated with palliative radiation therapy and are currently causing symptoms.You have a serious heart condition.You have had an allergic reaction to human serum albumin in the past.You have a history of neurological problems caused by polio virus infection.You are allergic to pembrolizumab or nivolumab, or any of the other ingredients in these drugs.You are 18 years old or older.If you had a tumor biopsy within the last 4 months, and have not received any anti-cancer treatment since then, you may be able to use that same biopsy for this study.You had cancer in the past two years before the start of the trial.You had a serious infection within the last 4 weeks before the trial starts.You must have at least one lesion that can be safely biopsied without significant risk. Lesions in high-risk areas like the brain, lung, pancreas, and certain parts of the digestive tract may not be eligible for biopsy.You must have at least one melanoma lesion that is visible or can be felt, and it must be at least 10 mm in size. Alternatively, you can have multiple lesions that can be injected, as long as they add up to at least 10 mm in size and the smallest lesion is at least 5 mm in size.You have received a recommended vaccine against PV (poliovirus) and received a booster shot of trivalent IPOL® (made by Sanofi-Pasteur SA) between 1 to 6 weeks before the start of the study.You have melanoma that cannot be surgically removed and are willing to have a biopsy before and during the study.You cannot participate if your cancer has spread to multiple distant parts of your body (M1c or M1d disease).
Research Study Groups:
This trial has the following groups:- Group 1: Arm 2: Lerapolturev and anti-PD-1
- Group 2: Arm 1: Lerapolturev Only
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Could you elaborate on the safety of PVSRIPO for human consumption?
"Data substantiating the efficacy of PVSRIPO is limited, but its safety profile has been tested in a Phase 2 trial; as such, our team at Power indicated it with an assigned score of 2."
Answered by AI
What are the desired outcomes of this clinical experiment?
"This clinical research study, scheduled to span 24 months, evaluates the Frequency and severity of treatment-emergent adverse events. Secondary endpoints include Duration of Response (DOR), Disease Control Rate-6months (DCR-6mo) and Disease Control Rate (DCR)."
Answered by AI
To what extent is this clinical trial accommodating individuals seeking treatment?
"Affirmative. Clinicaltrials.gov documents demonstrate that this medical research, which was first launched on November 17th 2020, is still enrolling participants. A total of 56 subjects need to be recruited from 25 distinct sites."
Answered by AI
Are there any open slots to join this clinical experiment?
"Indeed, clinicaltrials.gov confirms that this research endeavour is actively searching for participants. It was first published on November 17th 2020 and the latest update was issued on May 31st 2022. The study requires 56 volunteers across 25 sites."
Answered by AI
Where are the sites that offer this clinical trial?
"For this medical experiment, potential participants can be registered at UC Irvine Medical Center, Chao Family Comprehensive Cancer Center in Orange, California, Cancer Treatment Centers of America in Atlanta, Georgia and Community Cancer Centre North Indiana University in Indianapolis. Additionally there are 25 other sites that are partaking in the trial."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger